international regulatory cooperation on proper use of traditional medicine
Download
Skip this Video
Download Presentation
International Regulatory Cooperation on Proper Use of Traditional Medicine

Loading in 2 Seconds...

play fullscreen
1 / 26

International Regulatory Cooperation on Proper Use of Traditional Medicine - PowerPoint PPT Presentation


  • 427 Views
  • Uploaded on

International Regulatory Cooperation on Proper Use of Traditional Medicine. Dr Xiaorui Zhang Coordinator Traditional Medicine Department of Essential Drugs and Traditional Medicine World Health Organization. Ethiopia. Benin. Populations using traditional medicine for primary health care.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'International Regulatory Cooperation on Proper Use of Traditional Medicine' - zeal


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
international regulatory cooperation on proper use of traditional medicine
International Regulatory Cooperation on Proper Use of Traditional Medicine

Dr Xiaorui ZhangCoordinator

Traditional Medicine

Department of Essential Drugs and Traditional MedicineWorld Health Organization

populations using tm cam worldwide
Ethiopia

Benin

Populations using traditional medicine for primary health care

India

Rwanda

Tanzania

Uganda

Populations in developed countries who have used complementary and alternative medicine at least once

Canada

France

Australia

USA

Populations using TM/CAM worldwide

Germany

Sources: Eisenberg DM et al. 1998; Fisher P & Ward A, 1994; Health Canada, 2001;

World Health Organization, 1998; and government reports submitted to WHO.

slide3
Procedure for developing a new chemical drug

Duration: at least 13 years

Cost: at least US$ 100 million

difficulty for evaluation of herbal medicines
Difficulty for evaluation of herbal medicines

Reported by Prof Yeeng -chi Cheng, Yale Medical School 2001

The combination of 4 plants creates powerful synergy for maximum

anti-tumour effect

Removing any one of the 4 plants weakens the effectiveness of the formula

major problems of international herbal markets
Major problems of international herbal markets
  • Quality problems
      • Quality inconsistence
      • Use wrong species
      • Labelling problem
      • lack precautions
      • Including heavy metals
      • Including chemical substance or illegal substance without announcement
  • Other problems
      • Lack registration information of products in in the original countries
      • Lack producer information in the original countries
      • Lack communication between national drug authorities of imported and exported countries
who global survey and database of national policy and regulation of tm cam
WHO Global Survey and Database of National Policy and Regulation of TM/CAM
  • WHO Global Survey and Database of National Policy and Regulation of TM/CAM and Herbal Medicines including information from 141 countries, 2004
  • Summary report of the global survey on national policy on traditional medicine and regulation of herbal medicines2005
number of member states with recently established herbal medicines law or regulation
Number of Member States with Recently Established Herbal Medicines Law or Regulation

65% of respondents have established herbal medicines law or regulation

42 (49%) declared regulations were in the process of being developed.

Number of Countries before 1986: 14

Number of Countries Total: 83

regulatory status of herbal medicines
Regulatory status of herbal medicines

Respondents were able to answer with more than one option, if applicable, so the total number exceeds number of respondents

types of claims allowed for herbal medicines
Types of claims allowed for herbal medicines

Respondents were able to answer with more than one option, if applicable, so the total number exceeds number of respondents

slide11
Traditional Medicines & Health Supplements Product Working Group (TMHS – PWG)

Why need to set up the TMHS-PWG

  • ASEAN consider the need to remove technical barriers of trade in order to facilitate the implementation of the Common Effective Preferential Tariff (CEPT) to realize the ASEAN Free Trade Agreement (AFTA) and to create a stable, prosperous and highly competitive ASEAN economic region.
  • To respond the new dynamics of the global challenges, ASEAN leaders have also approved to pursue accelerated integration of eleven priority sectors in 2010 which include Traditional Medicines and Health Supplement Products and formed a Product Working Group  Traditional Medicines & Health Supplements Product Working Group (TMHS – PWG)
slide12
Traditional Medicines & Health Supplements Product Working Group (TMHS – PWG)

Objectives

  • Exchange, review and analyze information on the existing regulatory framework/regime including standard, definition, terminologies, and technical infrastructure in Member Countries.
  • Study the existing regulatory framework/regime of selected countries and internationally accepted technical guidelines
  • Enhance the technical infrastructure including mutual confidence in testing and conformity assessment
  • Identify areas for possible harmonization and MRAs
slide13
Working programme of ASIAN TMHS – PWG

1. ASEAN consensus on specific area of technical requirements for harmonization, achieved

OBJECTIVE 1

1.2.

Comparative study on International and other regional technical requirements for TMHS, conducted

1.1.

Exchange of information and analysis of the existing standard definition, terminologies, regulation & procedures amongst ASEAN Member Countries

1.3.

Specified areas on the technical requirements for harmonization agreed upon among Member Countries

STRATEGIES

EXPECTED OUTPUTS

Template for

exchange of

information

developed and

agreed upon.

Technical

requirements

(including

terminology and

definition)

of Member

Countries

compiled

and analyzed

Profile of

Technical

requirements

of

Member

Countries

developed

Terminology

and definition

on TMHS

standardized

in ASEAN

Technical

Requirements

and guidelines

of international

and other

regional

organization

compiled,

compared and

analyzed

Technical

requirements

of selected

other countries compiled,

compared

and analyzed

Appropriate model for ASEAN recommended

Specific Areas for

Harmonization

identified

and agreed upon

slide14
Western Pacific Regional Forum for the Harmonization of Herbal Medicines (FHH)
  • Why need to set up the FHH
  • Traditional Chinese medicine has been commonly used and

traded with similar theory system among these countries.

  • However, the quality standards and technical requirements in

these countries vary.

  • There is a need for cooperation in harmonization of standards

for traditional Chinese medicines.

  • Seven founding member parties:
  • 1. Australia 2. China
  • 3. Japan 4. Republic of Korea
  • 5. Singapore 6. Viet Nam
  • 7. Hong Kong (SAR China)
slide15
Western Pacific Regional Forum for the Harmonization of Herbal Medicines (FHH)

Nature of FHH

  • The FHH is a technical forum involving drug regulatory authorities of founding member parties to explore the way and measures for achieving the objectives set up by founding parties.
  • The role of the FHH is to provide technical documents and consensus on technical issues related to safety, efficacy and quality of herbal medicine.
western pacific regional forum for the harmonization of herbal medicines fhh
Western Pacific Regional Forum for the Harmonization of Herbal Medicines (FHH)
  • To provide a scientific basis for improvement or development of standards in safety, quality and efficacy of herbal medicines;
  • To reduce duplication of efforts;
  • To create economic use of valuable resources;and
  • To address lack of standards in areas of public health importance to regulatory agencies.
western pacific regional forum for the harmonization of herbal medicines fhh17
Western Pacific Regional Forum for the Harmonization of Herbal Medicines (FHH)

Secretariat (Provisional)

Hong Kong

Standing Committee

Sub-committee II

Quality Assurance & Information

Sub-committee I

Nomenclature & Standardization

Nomenclature

EWG

Good Agricultural Practice

EWG

Information on General test

EWG

Good Manufacturing Practice

EWG

Validated Analytical Method

EWG

Adverse Drug Reaction, Sub-committee III

Testing method in Monograph

EWG

ChemicalReference Standards and Reference of Medicinal Plant Materials

EWG

slide18
European Union

1. European Parliament(representation of the will of the EU citizens; legislative power; control over community institutions)

2. European Commission(executive body)

3. Council of the EU (legislative body)

Agencies of the MS and of the European Union (EMEA)

Specific Committee on Herbal Medicinal Products

committee on herbal medicinal products
Committee on Herbal Medicinal Products
  • Austria France Lithuania Slovenia
  • Estonia Germany Luxembourg Spain
  • Belgium Greece Malta Sweden
  • Cyprus Hungary Netherlands United Kingdom
  • Czech Rep. Ireland Poland
  • Denmark Italy Portugal
  • Finland Latvia Slovak Republic

EEA Members:

Norway, Iceland

Observer: EDQM/Europ. Pharm.

Romania; Bulgaria

slide20
Legal and technical requirements for herbal medicines
  • EU Council: a European approach to non-conventional medicine resolution 1026, 1999
  • EU Commission: the Directive 2001/83/EC as regards traditional medicinal products, amended by 2004
  • EMEA: the evidence of safety and efficacy required for well-established herbal medicinal products in bibliographic application 1999
  • EMEA: the implementation of different levels of scientific evidence in core-data for herbal drugs 2003
slide21
Marketing Authorisation of Herbal Medicinal Products in the EU

National Authorisation

Directive 2001/83/ECof the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.

basis for:

Mutual Recognition of marketing authorizationsDecentralized marketing authorizations

who working group meeting on international regulatory cooperation on herbal medicines
WHO Working group meeting on international regulatory cooperation on herbal medicines
  • WHO Working group meeting on regulatory cooperation on herbal medicines in Ottawa, Canada from 28 to 30 November 2005 hosted by the Health Products and Food Branch of Health Canada.
  • 29 regulatory authorities from 16 countries participated,
  • regulatory authorities representing each of the 6 regional/sub-regional/inter-regional regulatory cooperation groups including Forum on Harmonization of Herbal Medicines (FHH), the Pan American National Drug Regulatory Authorities Harmonization (PANDRH), the European Herbal Medicines Committee, the ASEAN Product Working Group on Traditional Medicines and Health Supplements (TMHSPWG) and the Latin American Parliament (PARLATINO)
international regulatory cooperation on herbal medicines irch
International regulatory Cooperation on Herbal Medicines (IRCH)

Objectives

  • globally promote and facilitate the safe use of herbal medicines, including through regional initiatives, through sharing information and fostering dialogue;
  • facilitate and strengthen cooperation between national drug regulatory authorities by sharing experience and information related to the regulation, safety and quality of herbal medicines;
  • further discuss existing requirements and standards to promote the regulation, safety and quality of herbal medicines;
  • further share research and knowledge of traditional medicines to reduce duplication;
  • recommend future activities to WHO related to the safe use of herbal medicines;
  • recommend important issues to ICDRA for further discussion related to the safe use herbal medicines.
international regulatory cooperation on herbal medicines irch25
International regulatory Cooperation on Herbal Medicines (IRCH)

Initial scope of activities of IRCH

IRCH is in the initial stages. There are two main activities:

  • Information sharing on technical matters related to regulatory information of herbal medicines via electronic communication as the main tool, on a daily basis, through an Information Focal Point nominated by each Member Country of IRCH.
  • Convening annual meetings of IRCH.

Second working group meeting will take place in

October 2006, Beijing, China

conclusion
Conclusion
  • Status and regulation of herbal medicines vary between country to country
  • The most difficulties for national authorities are the lack of research data, the lack of appropriate control mechanisms, the lack of education and training of providers and the lack of expertise.
  • Information exchange and sharing national experience is crucial aspect
  • WHO will provide support to the international and regional regulatory cooperation for herbal medicines
ad